Sio Gene Therapies Inc. Common Stock
SIOX
SIOX was delisted on the 22nd of March, 2023.
0 hedge funds and large institutions have $0 invested in Sio Gene Therapies Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $26K → $0 (-$26K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$26K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$26K | -64,170 | Closed |
|
SIOX Hedge Fund Activity: Q3 2023 in Review
0 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q3 2023, worth a combined $0 — down 100% from $26K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of SIOX and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Macquarie Group, exiting entirely with an estimated $26K sold.
- 0 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q3 2023, down from 1 in Q2 2023.
- Funds reported $0 of Sio Gene Therapies Inc. Common Stock stock for Q3 2023, down 100% quarter-over-quarter.
- 0 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q3 2023 and 1 closed out, a net change of -1 holder.
- The largest Sio Gene Therapies Inc. Common Stock seller in Q3 2023 was Macquarie Group, an estimated $26K sold.
Based on aggregated 13F filings for Q3 2023.